Infinity Pharmaceuticals, Inc. (INFI) today announced updated data from a Phase 1 study of IPI-145, its oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results